Rimonci Capital was established in 2016. The primary focus of the fund is to achieve the vision of “For better vision and insight” through globally exploring, incubating and investing in disruptive technology companies in the field of pre-clinical, clinical and other early stages while also actively driving transformation into the China market. Rimonci is positioned as a "Vertical Operator VC ". We are guided by the principle of "consulting, connecting and leading”, which help our portfolios grow robustly and sustainably in the long run, through a professionally constructed industry ecosystem, deep understanding of the industry, profound management skills and intensive work plans. We plan to complete the full life cycle architecture layout in the field of vision science in ten years as: Rimonci Starlight Vision Science Incubator (Include patent Fund) that focuses on laboratory research and proof of concept, Rimonci Stars Vision Science Venture Capital Fund (US Dollar Fund) that plays a vital role on uncovering the value of the startup, perfecting product development and conducting clinical trials, Rimonci Galaxy Vision Science Industry fund (RMB Fund) that drives the localization of high-potential product & technologies into the China market and most importantly to explore China domestic Vision science innovation.
6
Total Investments
5
Portfolio Companies
-
Exits
-
Industries
General Information
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Rimonci Capital
Recent Investments (6)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series C | •••••• | Mar 2021 | |
| Series A | •••••• | Aug 2020 | |
| Series B | •••••• | Jul 2020 | |
| Series A | •••••• | Jul 2020 | |
| Series A | •••••• | Nov 2017 | |
|
|
Venture Round | •••••• | Mar 2017 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.